Equity Overview
Price & Market Data
Price: $9.02
Daily Change: -$0.46 / 5.10%
Daily Range: $8.79 - $9.48
Market Cap: $1,383,929,600
Daily Volume: 1,777,767
Performance Metrics
1 Week: -5.05%
1 Month: -14.62%
3 Months: 17.60%
6 Months: -22.64%
1 Year: 7.51%
YTD: 15.35%
Company Details
Employees: 93
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California.